RandyW Posted September 11, 2006 Share Posted September 11, 2006 Novelos wins patent approval for cancer drug Boston Business Journal - 12:28 PM EDT Monday Print this Article Email this Article Reprints RSS Feeds Most Viewed Most Emailed Novelos Therapeutics has won preliminary patent approval for a new cancer drug. Novelos (OTC: NVLT), headquartered in Newton, Mass., said in a release that the U.S. Patent and Trademark Office has approved its application for NOV-002, currently in phase three testing for lung cancer. The drug is described by the company as a chemoprotectant and an immunomodulator, designed as a companion treatment to chemotherapy. The medication is supposed to enhance the effectiveness of radiation and protect patients from some of the side effects of cancer treatment. "This most recent addition to our IP portfolio further strengthens Novelos' proprietary position in the oxidized glutathione field in general and, in particular, around the structure of NOV-002," said Christopher Pazoles, Ph.D, Vice President of Research and Development of Novelos. Quote Link to comment Share on other sites More sharing options...
Join the conversation
You can post now and register later. If you have an account, sign in now to post with your account.